$APLS

Biogen shares rise 1.06% to $193.40 despite FDA extending Leqembi review to August 2026, offset by $5.6B Apellis acquisition and Spinraza approval momentum.

Complement inhibitors market projected for strong growth through 2036, driven by rising disease prevalence and C5/C3-targeted drug approvals across multiple indications.

Biogen partners with Alloy Therapeutics to advance antisense oligonucleotide therapies using the AntiClastic platform for multiple undisclosed disease indications.

McCormick merges with Unilever Foods for $29.1B while Sysco acquires Jetro for $29B; QVC explores bankruptcy amid retail distress.

Biogen acquires Apellis Pharmaceuticals for $5.6 billion in cash, gaining two FDA-approved therapies with $689M in 2025 projected sales and mid-to-high teens growth expectations.

RTW Investments establishes $193M position in Apellis Pharmaceuticals despite 29% stock decline, betting on turnaround potential of $689M revenue-generating biotech.

Apellis will discuss its complement-targeted drug portfolio at TD Cowen Healthcare Forum in March 2026, highlighting its approved therapies for eye and kidney diseases.